Company intelligence / Profile preview
Theregen
Huntington Beach, California, United Statespubmed.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
In early 2006, Theregen received FDA IND clearance and funding to initiate a Phase I safety trial for Anginera™, its lead regenerative heart therapy targeting acute myocardial ischemia. No further clinical results or updates are available in public sources since that time.
- Therapeutic areas
- Cardiovascular
- Modalities
- Cell therapyDevice
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sanderling Ventures
Beyond the preview
Go deeper on Theregen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theregen.